Overview

Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)

Status:
Completed
Trial end date:
2002-10-01
Target enrollment:
0
Participant gender:
All
Summary
This is a double-blind, placebo-controlled, randomized study lasting 8 weeks. Purpose of the study is two-fold: first, to use a pharmacological agent to treat symptoms of PTSD, and second, to explore neurobiological mechanisms of action of guanfacine.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
US Department of Veterans Affairs
VA Office of Research and Development
Treatments:
Guanfacine
Criteria
- Males and females, age 18-65

- Diagnosis of PTSD from combat or civilian trauma

- No major medical problems such as diabetes, cardiovascular disease

- Taking no psychiatric medication, or taking only one SSRI antidepressant